Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis 2026-09-22
  2. Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration 2026-09-21
  3. Diagnostic Value of Large Language Model-Extracted Gross Brain Findings in Neurodegenerative Diseases 2026-09-14

Studies

1,022 studies carry this tag.

Date range

1967 to 2026

Top journals

  • Neurology 106
  • Brain : a journal of neurology 71
  • Movement disorders : official journal of the Movement Disorder Society 53
  • Annals of neurology 34
  • The Lancet. Neurology 34

313 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-22 Lewy body dementia

    Simulation results were benchmarked against real-world population estimates, over a wide range of demographic and genetic parameters.

  2. Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-21 Digital health tools

    IntroductionFrontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials.

  3. Diagnostic Value of Large Language Model-Extracted Gross Brain Findings in Neurodegenerative Diseases

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-14 Lewy body dementia

    Gross brain findings help guide differential diagnosis, but their diagnostic value across major neurodegenerative diseases remains incompletely characterized.

  4. Vascular and neurodegenerative contributions to cognitive decline and multidomain progression in de novo Parkinsons disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-11 Brain scans and imaging

    Greater baseline WMH burden was associated with differential longitudinal progression in converters across eleven clinical outcomes, including cognition, gait, and functional independence (all q<0.05).

  5. Synaptic vesicle glycoprotein 2A PET imaging in parkinsonian α-synucleinopathies: a systematic review

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of neurology 2026-09-07 Disease mechanisms

    Synaptic dysfunction is increasingly recognized as an early and biologically relevant component of α-synucleinopathies.

  6. Dopaminergic therapy selectively amplifies hallucination susceptibility in patients with Parkinson's disease with cortico-striatal hyperconnectivity

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-03 Brain scans and imaging

    Dopamine replacement therapy (DRT) alleviates motor symptoms in Parkinsons disease (PD) but can trigger hallucinations in a subset of patients, yet the neural basis of this selective vulnerability is unknown.

  7. Elucidating shared genetic signals between type 2 diabetes and three neurodegenerative dementia phenotypes

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Human Genetics and Genomics Advances 2026-09-02 Genetics

    Type 2 diabetes (T2D) and dementia frequently co-occur, yet the biological mechanisms underlying this comorbidity remain incompletely understood.

  8. A Spanish grammaticality judgment task for neurodegenerative diseases: inflectional, transitivity, and word order comprehension in PPA and Alzheimer's Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-28 Long-term cohort studies

    Impairment in the comprehension of morphosyntactic and transitivity information does not feature in current diagnostic guidelines for primary progressive aphasia (PPA) or Alzheimers Diseases (AD), despite research reporting delayed sensitivity or insensitivity of these clinical populations to these linguistic domains.

  9. Genome-wide analyses reveal shared and distinct genetic architecture linking amyotrophic lateral sclerosis, sporadic frontotemporal dementia and cognitive traits

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-21 Genetics

    Cognitive and behavioural impairment frequently accompanies motor decline in amyotrophic lateral sclerosis (ALS), with 15% of cases meeting the diagnostic criteria for frontotemporal dementia (FTD).

  10. GCH1 genetic variation as a prognostic factor in Parkinsons disease across populations

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-19 How common it is

    BackgroundPathogenic variants in GCH1 have been associated with Parkinsons disease (PD), but the clinical phenotype and longitudinal disease course of GCH1-associated PD remain incompletely characterized.

  11. Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies

    ✓ Peer-reviewed alzhub usefulness score 31 out of 100. Open Science Framework 2026-08-01 Drug development

    Neurodegenerative disorders (NDDs), primarily alzheimer, dementia, parkinson, and rare NDD disease, present an escalating global health crisis, currently affecting over 55 million older adults worldwide.

  12. Mediterranean Diet and Neurodegenerative Diseases: Recent Advances from the Gut–Immune–Brain Axis to Multi-Omics-Guided Precision Nutrition

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cells 2026-07-17 Prevention trials

    The Mediterranean diet, rich in plant-based foods, olive oil, and fish, has been consistently associated with slower cognitive decline and reduced risk of neurodegeneration in observational studies and some clinical trials.

  13. Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurology 2026-07-01 Brain tissue and pathology

    = 0.015). In this autopsy-confirmed cohort, seizure susceptibility was associated with advanced tau pathology and CAA in AD.

  14. Lewy Bodies Are Not Associated With Neuronal or Synaptic Loss in Dementia With Lewy Bodies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuropathology and Applied Neurobiology 2026-06-01 Lewy body dementia

    Across both regions, no evidence of reduced total neuronal density was observed, but a modest reduction in parvalbumin interneurons was observed in the cingulate gyrus, and there were only modest reductions in some synaptic markers in DLB.

  15. Meeting the mental health needs of people with the complex neurodevelopment condition, Prader-Willi syndrome: a major challenge for mental health services

    ✓ Peer-reviewed alzhub usefulness score 30 out of 100. European Psychiatry 2026-06-01 Risk factors

    The behavioural and mental health needs of people with PWS result from the interactions between biological vulnerabilities associated with having PWS and living in a changing and demanding environment.

  16. Incidence and Prevalence of Dementia With Lewy Bodies

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. JAMA Neurology 2026-05-11 How common it is

    From 2520 records screened, 16 population-based studies were included and 12 contributed to meta-analyses.

  17. Effects of α‐synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2026-05-01 Disease mechanisms

    α -Syn positivity was detected in 9% of CU individuals, a lower rate than in clinically impaired participants with AD (16%) and LBD diagnoses (81%).

  18. Characterizing Individuals Fulfilling Clinical Criteria for Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Tertiary Memory Clinic

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2026-04-16 Brain tissue and pathology

    < 0.01). Using an operationalization of clinical criteria for LATE, 8.2% of participants with MCI or dementia from our tertiary memory clinic were classified as Possible-LATE, Probable-LATE, or LATE-AD.

  19. Parkinson’s disease dementia and hearing impairment, are they related? A UK biobank pilot analysis

    ✓ Peer-reviewed alzhub usefulness score 58 out of 100. Experimental Brain Research 2026-04-09 Long-term cohort studies

    Hearing impairment is implicated as a risk factor for the incidence of all-cause dementia.

  20. Locus coeruleus TDP-43 pathology in a community-based cohort: Clinical and pathological correlates

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Neuropathology & Experimental Neurology 2026-03-24 Brain tissue and pathology

    The locus coeruleus (LC) is the source of norepinephrinergic innervation in the human brain.

  21. Prevalence and clinical effects of Lewy Body pathology in non-prion rapidly progressive dementias: a retrospective cohort study

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer s Research & Therapy 2026-03-06 How common it is

    In the cohort, 39.2% (67/171) tested positive by α-syn SAA. α-syn SAA positivity was more frequently detected alone than in combination with biomarkers of AD pathology (25.1% vs. 14.0%). α-syn SAA+ status was independently associated with higher odds of fluctuating cognition (OR 2.99, 95%CI 1.46–6.25, p = 0.012), visual hallucinations (OR 2.41, 95%CI 1.24–4.75, p = 0.027), extrapyramidal signs (OR 4.57, 95%CI 2.35–9.11, p < 0.001) and akinetic mutism (OR 3.77, 95%CI 1.22–12.82, p = 0.038).

  22. Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C pathology

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain 2026-03-04 Brain tissue and pathology

    Our findings were compared to other published RNA sequencing data of tauopathies (Alzheimer's dementia, progressive supranuclear palsy and FTLD with MAPT), FTLD-TDP (subtypes A&B) and available proteomics of this cohort.

  23. EEG microstate alterations in Parkinson’s disease dementia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Scientific Reports 2026-02-27 Getting a diagnosis

    To investigate alterations in resting-state electroencephalogram (EEG) microstates across the cognitive spectrum of Parkinson's disease (PD) and to evaluate their utility as electrophysiological biomarkers of cognitive impairment.

  24. A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Nature Medicine 2026-02-16 Lewy body dementia

    Accurate diagnosis of dementia with Lewy bodies (DLB) remains challenging, with misdiagnosis potentially leading to harmful treatment decisions.

  25. Reasons for and against presymptomatic genetic testing in frontotemporal dementia: a qualitative study

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Human Genetics 2026-02-16 Lewy body dementia

    The majority of individuals at 50% risk of carrying a pathogenic variant causing frontotemporal dementia (FTD) chooses not to undergo presymptomatic genetic testing.

  26. Comparing phenotypic features between Parkinson’s disease dementia and dementia with Lewy bodies

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neurology 2026-02-01 Getting a diagnosis

    Patients with PDD showed a more severe phenotype than those with DLB, with higher scores in motor severity, hallucinations, delusions, somnolence, and urinary dysfunction (all p≤0.01).

  27. Vulnerability of anterior cingulate Von Economo neurons to FTLD-tauopathies in behavioral variant frontotemporal dementia

    ✓ Peer-reviewed alzhub usefulness score 34 out of 100. Cerebral Cortex 2026-02-01 Disease mechanisms

    Von Economo neurons (VENs) are unique spindle-shaped neurons that primarily reside in the anterior cingulate (ACC) and fronto-insular (FI) cortices.

  28. Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Neurology Open Access 2026-01-30 Genetics

    The study included 1,028 participants (mean age at baseline 76.4 years; 47.6% female): 521 with ADP, 96 with LBP, and 411 with mixed AD-LBP.

  29. Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2026-01-28 Getting a diagnosis

    This study highlights challenges for the reproducibility of α-syn SAA results across different protocols applied by different laboratories.

  30. Integrated bio-cooperative robotic platform for virtual cognitive training in Parkinson's disease: design and methodology of the OPERA project

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Frontiers in Neurology 2026-01-26 Prevention trials

    Mild cognitive impairment in Parkinson's disease (PD-MCI) can affect several cognitive domains, including attention, working memory, executive functions, language, visuospatial skills, and episodic memory, resulting in a progressive reduction of autonomy and an increased risk of dementia.

  31. Behavioral Variant Frontotemporal Dementia With C9orf72 Intermediate Repeat Expansion

    ✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer Disease & Associated Disorders 2026-01-01 Clinical safety

    Hexanucleotide repeat expansion in the chromosome 9 open reading frame 72 ( C9orf72 ) gene has been identified as the most common genetic cause of both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

  32. EEG network reorganization across Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2026-01-01 Lewy body dementia

    AD showed canonical slowing with delta/theta increases and posterior alpha loss.

  33. Effect of deep brain stimulation on patients with Parkinson’s disease with mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. BMJ Neurology Open 2026-01-01 Mild cognitive impairment

    Eight studies comprising 984 patients met inclusion criteria.

  34. Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Clinical Neurology 2026-01-01 Lewy body dementia

    In the central Lewy body diseases (LBDs) Parkinson's disease and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests, substantial central neurodegeneration has already occurred.

  35. Vagus Nerve Stimulation in the Management of Neurodegenerative Diseases: A Systematic Review of Advances in Animal Research and Clinical Applications

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Current Alzheimer research 2026-01-01 Inflammation and the immune system

    Vagus Nerve Stimulation (VNS) shows neuroprotective and anti-inflammatory effects in animal models of Alzheimer's and Parkinson's disease, but clinical results remain inconsistent due to variability in treatment duration, outcome measures, and reliance on subjective assessments.

  36. Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Annals of Clinical and Translational Neurology 2025-12-25 Getting a diagnosis

    After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA.

  37. Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Communications Medicine 2025-12-12 Lewy body dementia

    Accurate diagnosis of frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance remains challenging due to lack of clinical characterization, and standardized terminology.

  38. Transcriptomic analysis of plasma small extracellular vesicles identifies potential diagnostic biomarkers for Parkinson's disease dementia

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Parkinsonism & Related Disorders 2025-12-09 Getting a diagnosis

    We identified 51 transcriptome-wide significant (edgeR q < 0.05) DEGs, compared to controls, and 26 transcriptome-wide significant DEGs, compared to PD, in PDD plasma SEV.

  39. Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Molecular Sciences 2025-12-07 Inflammation and the immune system

    Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are the two most common forms of dementia due to neurodegeneration.

  40. Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE ε4 Carriers

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Neurology 2025-12-05 Genetics

    Growing evidence suggests that the APOE ε4 allele, a genetic risk factor for Alzheimer disease (AD), influences the clinical-pathologic features of Parkinson disease (PD).

  41. Epilepsia como manifestación temprana en el espectro de la enfermedad de Alzheimer: explorando la variante epiléptica

    ✓ Peer-reviewed alzhub usefulness score 26 out of 100. Acta neurológica colombiana 2025-12-05 Risk genes beyond APOE

    Con el envejecimiento de la población general, el número de pacientes con epilepsia de inicio tardío crece constantemente.

  42. Association between anosognosia and neuropsychiatric symptoms in Alzheimer’s disease dementia patients

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. Scientific Reports 2025-12-04 Cognitive tests and assessment

    Anosognosia, the lack of awareness of memory decline, and Neuropsychiatric Symptoms (NPS) are prevalent and debilitating symptoms in Alzheimer's disease (AD) dementia.

  43. Alterations in gut microbiota and plasma metabolites: a multi-omics study of mild cognitive impairment in Parkinson’s disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in Neuroscience 2025-12-01 Mild cognitive impairment

    Our multi-omics study revealed distinct gut microbiota and metabolite alterations in PD patients with cognitive impairment, highlighting gut-brain axis dysfunction.

  44. Depression preceding and following the diagnosis of Parkinson’s disease and Lewy body dementia

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. General Psychiatry 2025-12-01 Lewy body dementia

    We identified 17 711 patients with PD or LBD.

  45. Detection of TDP‐43 seeds in CSF of presymptomatic and symptomatic genetic FTD/ALS

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-12-01 Brain tissue and pathology

    TDP-43 seeding activity was detected in 67% of TDP-43-linked symptomatic patients, with a specificity of 93%.

  46. Functional capacity in Peruvian people with Alzheimer's disease and frontotemporal dementia

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer s & Dementia 2025-12-01 Lewy body dementia

    Functional impairment increased progressively from normal cognition to dementia.

  47. Gray and white matter pathology progression in Parkinson's disease patients that develop mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer s & Dementia 2025-12-01 Mild cognitive impairment

    All included PD patients were cognitively normal at baseline and had 6 years of follow-up assessments available for cognitive status.

  48. Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. MedComm 2025-12-01 Prevention and risk

    Parkinson's disease (PD) is a progressive neurodegenerative disorder with a growing global burden.

  49. Phenotypic Characterization of Recently Identified PSEN1 Genetic Variants in ADAD in Colombia

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01 Risk genes beyond APOE

    The sample included 61 participants (55.7% female), aged 18-58, with a median education of 12 years (IQR: 10-14).

  50. Representing the Cognitive Impairment Continuum of Alzheimer's Disease and Lewy Body Dementia with a Novel Finer‐Scale Cortical Representation via Disease Embedding Tree

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01 Cognitive tests and assessment

    The DET framework has achieved superior performance on the classification task across all the evaluation metrics compared to the traditional machine learning based methods, as demonstrated in Table 1.

From across this tag

9 of the 1,021 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

All topic tags with their study counts